Related Experiment Videos

Evaluating the effects of sacubitril/valsartan with ST-elevated myocardial infarction: a systematic review and

Ajay Kumar1, Rohit Kumar2, Simran Kumari3

  • 1Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan.

Annals of Medicine and Surgery (2012)
|June 8, 2026
PubMed

Insights

Sacubitril/valsartan significantly reduces major adverse cardiovascular events and hospitalizations for heart failure in ST-segment elevation myocardial infarction (STEMI) patients. This therapy also improves left ventricular ejection fraction without increasing safety risks.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • ST-segment elevation myocardial infarction (STEMI) is a major cause of cardiovascular morbidity and mortality globally.
  • Current guidelines recommend angiotensin-converting enzyme inhibitors (ACEIs) post-STEMI, but newer agents like sacubitril/valsartan show potential for enhanced cardioprotection.

Purpose of the Study:

  • To systematically evaluate and compare the efficacy and safety of sacubitril/valsartan versus ACEIs in STEMI patients.
  • To determine if sacubitril/valsartan offers superior outcomes compared to standard ACEI therapy.

Main Methods:

  • A meta-analysis of five randomized controlled trials (RCTs) involving 4915 participants.
  • Data were synthesized using a random-effects model to calculate risk ratios and weighted mean differences with 95% confidence intervals.

Main Results:

  • Sacubitril/valsartan significantly reduced major adverse cardiovascular events (MACE) and hospitalizations for heart failure (HHF).
  • Improved left ventricular ejection fraction (LVEF) and reduced NT-proB-type natriuretic peptide (NT-proBNP) levels were observed.
  • No significant differences in recurrent myocardial infarction, cardiovascular death, all-cause mortality, or adverse safety events were noted.

Conclusions:

  • Sacubitril/valsartan therapy is effective in reducing MACE and HHF and improving LVEF in STEMI patients.
  • The therapy demonstrates a favorable safety profile compared to ACEIs.
  • Further large-scale RCTs are warranted to solidify these findings and inform clinical guidelines.
Abstract

Keywords:
STEMIcardiovascular outcomesheart failuremeta-analysissacubitril/valsartan

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...